{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:17:09Z","timestamp":1769559429908,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":2926,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1093\/annonc\/mdr468","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T13:43:25Z","timestamp":1324043005000},"page":"viii29-viii32","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S8","title":["Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor"],"prefix":"10.1016","volume":"22","author":[{"given":"N.","family":"Katsumata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr468_bb0010","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/IGC.0b013e31821ce75d","article-title":"First-line therapy in ovarian cancer trials","volume":"21","author":"Thigpen","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdr468_bb0015","doi-asserted-by":"crossref","first-page":"88S","DOI":"10.1002\/j.1875-9114.1996.tb03631.x","article-title":"New approaches to adjuvant chemotherapy for breast cancer","volume":"16","author":"Hudis","year":"1996","journal-title":"Pharmacotherapy"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdr468_bb0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1634\/theoncologist.6-suppl_3-30","article-title":"Theoretical concepts and the emerging role of taxanes in adjuvant therapy","volume":"6","author":"Norton","year":"2001","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdr468_bb0025","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","article-title":"Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","volume":"21","author":"Henderson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr468_bb0030","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr468_bb0035","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr468_bb0040","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/jnci\/djq409","article-title":"Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"102","author":"Bonilla","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr468_bb0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ijc.1591","article-title":"Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells","volume":"97","author":"Tan","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdr468_bb0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00685842","article-title":"Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines","volume":"32","author":"Lopes","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdr468_bb0055","first-page":"816","article-title":"Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death","volume":"56","author":"Jordan","year":"1996","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr468_bb0060","first-page":"3620","article-title":"Mechanisms of Taxol-induced cell death are concentration dependent","volume":"58","author":"Torres","year":"1998","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr468_bb0065","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1525-1438.2007.00811.x","article-title":"A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer","volume":"17","author":"Leiser","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdr468_bb0070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jjco\/hyh093","article-title":"Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer","volume":"34","author":"Kikuchi","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"10.1093\/annonc\/mdr468_bb0075","article-title":"A phase II trial of weekly paclitaxel\/carboplatin (TJ) as salvage chemotherapy in patients with relapsed ovarian cancer","volume":"20","author":"Katsumata","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdr468_bb0080","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ygyno.2004.03.046","article-title":"A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma","volume":"96","author":"Rose","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdr468_bb0085","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00280-007-0466-z","article-title":"Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO","volume":"61","author":"Sehouli","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdr468_bb0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.critrevonc.2007.12.005","article-title":"A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study","volume":"66","author":"Pignata","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdr468_bb0095","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1200\/jco.2008.26.15_suppl.5506","article-title":"Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology","volume":"26","author":"Isonishi","year":"2008","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdr468_bb0100","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr468_bb0105","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-79-4-604","article-title":"Creatinine clearance: bedside estimate","volume":"79","author":"Jelliffe","year":"1973","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdr468_bb0110","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr468_bb0115","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr468_bb0120","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr468_bb0125","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1200\/JCO.2008.20.8793","article-title":"Japanese\u2013US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics","volume":"27","author":"Gandara","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr468_bb0130","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/clinchem\/35.2.312","article-title":"Assessment of renal function by inulin clearance: comparison with creatinine clearance as determined by enzymatic methods","volume":"35","author":"Apple","year":"1989","journal-title":"Clin Chem"},{"key":"10.1093\/annonc\/mdr468_bb0135","first-page":"4733","article-title":"Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level","volume":"6","author":"Ando","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr468_bb0140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdr468_bb0145","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdr468_bb0150","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419388659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419388659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/Suppl_8\/viii29\/601070\/mdr468.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T23:27:39Z","timestamp":1713223659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419388659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":29,"alternative-id":["S0923753419388659"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr468","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}